Peritoneal Mesothelioma

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 12 6 15 17 71
Malignant Mesothelioma of Peritoneum 12 71
Advanced Malignant Mesothelioma of Peritoneum 12
Advanced Malignant Peritoneal Mesothelioma 12
Advanced Peritoneal Malignant Mesothelioma 71


External Ids:

Disease Ontology 12 DOID:1788
NCIt 49 C8704 C9350
ICD10 32 C45.1
UMLS 71 C0346109 C0854886 C1377610

Summaries for Peritoneal Mesothelioma

Disease Ontology : 12 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary : Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to benign peritoneal mesothelioma and malignant peritoneal mesothelioma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is LATS2 (Large Tumor Suppressor Kinase 2), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Ranpirnase and Topoisomerase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include peritoneum, lung and ovary, and related phenotypes are Decreased cell migration and Decreased sensitivity to paclitaxel

Wikipedia : 74 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 459)
# Related Disease Score Top Affiliating Genes
1 benign peritoneal mesothelioma 34.4 MUC1 CEACAM5 CALB2
2 malignant peritoneal mesothelioma 34.0 NF2 MUC1 EGFR CDKN2A BAP1
3 benign mesothelioma 32.4 WT1 CEACAM5 CALB2
4 rare tumor 31.6 NF2 LATS2
5 asbestosis 30.9 WT1 THBD MUC1 CALB2
6 pseudomyxoma peritonei 30.8 MUC16 MUC1 CEACAM5
7 pleural disease 30.6 EGFR CEACAM5 CALB2 BAP1
8 tuberculous peritonitis 30.5 MUC16 CEACAM5
9 adenomatoid tumor 30.5 WT1 THBD CALB2
10 cholecystitis 30.5 MUC1 EGFR CDKN2A
11 primary peritoneal carcinoma 30.4 PGR MUC16 EGFR
12 spindle cell carcinoma 30.3 PGR MUC1 ESR1
13 malignant biphasic mesothelioma 30.3 WT1 THBD CALB2
14 intravenous leiomyomatosis 30.2 PGR ESR1
15 neurilemmoma 30.2 NF2 MUC1 CALB2
16 pericardial mesothelioma 30.2 MUC16 MUC1 CALB2
17 malignant epithelial mesothelioma 29.9 WT1 THBD CEACAM5 CALB2
18 papillary adenocarcinoma 29.9 PGR MUC16 MUC1 CEACAM5
19 leiomyomatosis 29.7 WT1 PGR ESR1 CALB2
20 papillary carcinoma 29.7 PGR MUC1 MET ESR1 CALB2
21 sarcomatoid mesothelioma 29.6 WT1 THBD MUC1 CDKN2A CALB2 BAP1
22 verrucous carcinoma 29.6 PTEN EGFR CDKN2A
23 lung adenoma 29.6 PTEN EGFR CDKN2A
24 wilms tumor 1 29.5 WT1 PGR ESR1 EGFR CALB2
25 tongue cancer 29.4 PTEN EGFR CDKN2A
26 gastrointestinal stromal tumor 29.3 WT1 PTEN NF2 EGFR CDKN2A
27 li-fraumeni syndrome 29.3 PTEN ESR1 EGFR CDKN2A
28 papilloma 29.2 PTEN ESR1 EGFR CDKN2A
29 endometriosis 29.2 PTEN PGR MUC16 ESR1 CALB2
30 mesothelioma, malignant 29.2 WT1 THBD NF2 MUC16 MUC1 MET
31 peritoneum cancer 29.0 WT1 NF2 EGFR CEACAM5 CDKN2A CALB2
32 squamous cell carcinoma 29.0 PTEN MUC1 EGFR CEACAM5 CDKN2A
33 mucinous adenocarcinoma 29.0 PGR MUC16 MUC1 ESR1 EGFR CEACAM5
34 teratoma 29.0 PTEN ESR1 CEACAM5 CDKN2A CALB2
35 malignant pleural mesothelioma 29.0 WT1 THBD NF2 MUC1 MET EGFR
36 colon adenocarcinoma 29.0 PTEN ESR1 EGFR CEACAM5 CALB2
37 adenocarcinoma 28.9 PTEN MUC1 MET EGFR CEACAM5 CDKN2A
38 malignant peripheral nerve sheath tumor 28.9 WT1 NF2 MUC1 MET EGFR CDKN2A
39 cystadenoma 28.8 PTEN PGR MUC16 MUC1 CEACAM5 CALB2
40 renal cell carcinoma, nonpapillary 28.6 WT1 PTEN MUC1 MET EGFR CALB2
41 kidney cancer 28.5 WT1 PTEN MET EGFR CDKN2A
42 ovarian serous cystadenocarcinoma 28.0 PTEN PGR MUC16 MUC1 EGFR CEACAM5
43 melanoma, uveal 27.8 PTEN MET LATS1 HMGB1 EGFR CDKN2A
44 gastric adenocarcinoma 27.8 PTEN MUC1 MET LATS2 ESR1 EGFR
45 lung cancer susceptibility 3 27.3 THBD PTEN MUC16 MUC1 MET ESR1
46 ovarian cancer 26.6 WT1 PTEN PGR MUC16 MUC1 MET
47 benign multicystic peritoneal mesothelioma 12.8
48 peritoneal cystic mesothelioma 11.7
49 eccrine porocarcinoma 10.5 MUC1 CEACAM5
50 liver fibroma 10.5 THBD CALB2

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:

Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:

abdominal pain

GenomeRNAi Phenotypes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 EGFR LATS1 MET MUC1 NF2
2 Decreased sensitivity to paclitaxel GR00112-A-0 8.8 LATS1 PTEN WT1

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 BAP1 CDKN2A CLDN15 EGFR ESR1 LATS1
2 cardiovascular system MP:0005385 10.28 BAP1 CDKN2A EGFR ESR1 LATS1 LATS2
3 endocrine/exocrine gland MP:0005379 10.26 BAP1 CDKN2A CLDN15 EGFR ESR1 LATS1
4 embryo MP:0005380 10.24 BAP1 CDKN2A EGFR ESR1 LATS2 MET
5 liver/biliary system MP:0005370 10.13 CDKN2A EGFR ESR1 LATS1 LATS2 MET
6 digestive/alimentary MP:0005381 10.11 BAP1 CDKN2A CLDN15 EGFR ESR1 MET
7 integument MP:0010771 10.11 BAP1 CDKN2A EGFR ESR1 LATS1 NF2
8 neoplasm MP:0002006 10.07 BAP1 CDKN2A EGFR ESR1 LATS1 MET
9 muscle MP:0005369 10.06 BAP1 CDKN2A EGFR ESR1 LATS2 MET
10 no phenotypic analysis MP:0003012 9.97 BAP1 CDKN2A EGFR ESR1 LATS1 LATS2
11 normal MP:0002873 9.96 CALB2 EGFR ESR1 LATS1 LATS2 MET
12 renal/urinary system MP:0005367 9.7 EGFR ESR1 MET NF2 PTEN THBD
13 reproductive system MP:0005389 9.65 BAP1 CDKN2A EGFR ESR1 LATS1 NF2
14 respiratory system MP:0005388 9.28 BAP1 CDKN2A EGFR ESR1 MET NF2

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Ranpirnase Investigational Phase 3 196488-72-9
2 Topoisomerase Inhibitors Phase 3
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
Pancrelipase Approved, Investigational Phase 2 53608-75-6
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
Gemcitabine Approved Phase 2 95058-81-4 60750
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
Fluorouracil Approved Phase 2 51-21-8 3385
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
Promethazine Approved, Investigational Phase 2 60-87-7 4927
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
Pembrolizumab Approved Phase 2 1374853-91-4
Melphalan Approved Phase 2 148-82-3 4053 460612
nivolumab Approved Phase 2 946414-94-4
Ipilimumab Approved Phase 2 477202-00-9
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
leucovorin Approved Phase 2 58-05-9 6006 143
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
Glutamic acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
Tremelimumab Investigational Phase 2 745013-59-6
29 Interferon-gamma Phase 2
30 pancreatin Phase 2
31 Anti-Infective Agents Phase 2
32 Antimetabolites Phase 2
33 Antiviral Agents Phase 2
34 interferons Phase 1, Phase 2
35 Antirheumatic Agents Phase 1, Phase 2
36 Hydrocortisone 17-butyrate 21-propionate Phase 2
37 Hydrocortisone hemisuccinate Phase 2
38 Ranitidine bismuth citrate Phase 2
39 Chelating Agents Phase 2
40 Protective Agents Phase 2
41 Antidotes Phase 2
42 sodium thiosulfate Phase 2
43 Antitubercular Agents Phase 2
44 Antioxidants Phase 2
45 Vaccines Phase 1, Phase 2
46 Anti-Inflammatory Agents Phase 1, Phase 2
47 Cyclooxygenase 2 Inhibitors Phase 1, Phase 2
48 poly(I).poly(c12,U) Phase 1, Phase 2
49 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
50 Analgesics, Non-Narcotic Phase 1, Phase 2

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
3 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
4 Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial Unknown status NCT00454519 Phase 2
5 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
6 Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations Completed NCT01592383 Phase 2 erlotinib hydrochloride
7 Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Completed NCT00859469 Phase 2 Oxaliplatin;Gemcitabine
8 ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
9 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
10 A Pilot/ Phase 2 Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma, Lung Cancer or Pancreatic Cancer Completed NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
11 Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
12 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
13 A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies Completed NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
14 Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma Recruiting NCT03644550 Phase 2 LMB-100
15 Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT03086538 Phase 2 Pemetrexed;Tarceva 100Mg Tablet
16 Phase II Single-Blind Randomized Trial Comparing Morbidity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis Recruiting NCT03073694 Phase 2 Mitomycin c;Melphalan
17 Hyperthermic Intraperitoneal Chemotherapy in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy. Phase II Study Recruiting NCT03275194 Phase 2
18 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
19 A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
20 Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin Active, not recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
21 Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma Not yet recruiting NCT03875144 Phase 2 Cisplatin;Pemetrexed
22 Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas Completed NCT00003046 Phase 1
23 Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
24 A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy Recruiting NCT03608618 Phase 1
25 Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study) Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
26 A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 With or Without Nab-Paclitaxel (Abraxane) in Patients With Malignant Mesothelioma Active, not recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
27 A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy Active, not recruiting NCT02463877 Phase 1
28 A Phase 1b Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity Not yet recruiting NCT04000906 Phase 1 NAB paclitaxel;Cisplatin
29 A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Terminated NCT03436732 Phase 1 LMB-100;SEL-110
30 French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry) Unknown status NCT02834169
31 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
32 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
33 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer Completed NCT03931304
34 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Recruiting NCT01416714
35 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers Recruiting NCT01950572
36 A Prospective Audit of Perioperative Parameters of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Recruiting NCT02754115
37 Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma Not yet recruiting NCT03867578
38 Implementation of a Cardiac Coherence Program to Reduce Anxiety in Patients With Peritoneal Carcinosis Treated by Surgery: Pilot Study Not yet recruiting NCT04024917

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

The Foundational Model of Anatomy Ontology organs/tissues related to Peritoneal Mesothelioma:


MalaCards organs/tissues related to Peritoneal Mesothelioma:

Lung, Ovary, Liver, Colon, Lymph Node, Pancreas, Small Intestine

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 1279)
# Title Authors PMID Year
Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series. 61
31832913 2019
Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: current challenges and how to overcome them. 61
31725340 2019
Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. 61
31792692 2019
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. 61
31838086 2019
Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. 61
31287877 2019
Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study. 61
31620941 2019
Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease? 61
31757660 2019
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. 61
31752449 2019
Focal Peritoneal Mesothelioma Demonstrated on FDG PET/CT. 61
31107757 2019
The value of BAP1 expression and CDKN2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. 61
31713897 2019
Anaplastic lymphoma kinase (ALK) Gene Rearrangement in Children and Young Adults with Mesothelioma. 61
31783178 2019
Peritoneal sarcomatoid mesothelioma in a sika deer. 61
31413229 2019
Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance. 61
31583526 2019
[A Case of Malignant Peritoneal Mesothelioma Resected Four Times in Five Years]. 61
31631161 2019
Malignant peritoneal mesothelioma diagnosed 50 years post-radiotherapy for ovarian cancer in a patient with a history of multiple malignancies: An autopsy case. 61
31475068 2019
Primary Malignant Mesothelioma of the Peritoneum Mistaken for Peritoneal Tuberculosis due to Elevated Cancer Antigen 125. 61
31650800 2019
Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. 61
31602579 2019
Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics. 61
31661685 2019
Localized biphasic malignant peritoneal mesothelioma presenting as a rectal tumor. 61
31602554 2019
Peritoneal mesothelioma in Sweden: A population-based study. 61
31483564 2019
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. 61
31283845 2019
Multicystic peritoneal mesothelioma: a systematic review of the literature. 61
31667333 2019
A Rare Complication of Diffuse Malignant Peritoneal Mesothelioma: Spontaneous Ileal Perforation. 61
31496592 2019
Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. 61
31570769 2019
Malignant peritoneal mesothelioma in a boar who lived in Calabria (Italy): Wild animal as sentinel system of human health. 61
31132706 2019
The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma. 61
31709947 2019
Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy. 61
31285358 2019
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. 61
31267971 2019
Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 61
31253545 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes. 61
29589675 2019
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. 61
31417958 2019
[A Case of Peritoneal Mesothelioma Diagnosed by Ileus]. 61
31273181 2019
Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma. 61
31417959 2019
Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study. 61
30953970 2019
[Clinical characteristics of malignant peritoneal mesothelioma misdiagnosed as tuberculous peritonitis: a report of 6 cases]. 61
31269586 2019
Peritoneal mesothelioma mortality in Italy: Spatial analysis and search for asbestos exposure sources. 61
31030080 2019
[Recent Developments in the Regional Treatment of Peritoneal and Pleural Tumours (incl. HIPEC and HITOC)]. 61
31167266 2019
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. 61
31092657 2019
[Benign multicystic peritoneal mesothelioma]. 61
31104501 2019
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. 61
30794891 2019
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience. 61
31065962 2019
Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. 61
31069554 2019
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. 61
30862609 2019
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. 61
30975761 2019
Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma. 61
30132292 2019
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. 61
30914057 2019
Benign Multicystic Peritoneal Mesothelioma (BMPM) as a rare cause of abdominal pain in a young male: case report and review of the literature. 61
30891172 2019
Localized multiple malignant epithelioid peritoneal mesotheliomas arising from the hepatoduodenal ligament and diaphragm: a case report. 61
30879467 2019
Benign multicystic mesothelioma: a case report of recurrent disease in a young adult with familiarity for renal cell carcinoma. 61
31131816 2019
Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. 61
30473172 2019

Variations for Peritoneal Mesothelioma

ClinVar genetic disease variations for Peritoneal Mesothelioma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LATS1 NM_004690.4(LATS1):c.2636G>A (p.Trp879Ter)SNV Likely pathogenic 619199 rs1408705745 6:149997831-149997831 6:149676695-149676695
2 LATS2 NM_014572.3(LATS2):c.2699_2700insC (p.Val901fs)insertion Likely pathogenic 619198 rs1565941245 13:21553902-21553903 13:20979763-20979764
3 MECOM NM_004991.4(MECOM):c.262C>T (p.Pro88Ser)SNV Uncertain significance 619200 rs1560202272 3:169099088-169099088 3:169381300-169381300

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

Pathways related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
5 11.32 WT1 ESR1 EGFR
7 10.79 NF2 LATS2 LATS1

GO Terms for Peritoneal Mesothelioma

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.7 WT1 PGR MET HMGB1 ESR1 EGFR
2 negative regulation of cell proliferation GO:0008285 9.65 WT1 PTEN NF2 CDKN2A BAP1
3 G1/S transition of mitotic cell cycle GO:0000082 9.61 LATS2 LATS1 CDKN2A
4 regulation of protein stability GO:0031647 9.54 PTEN NF2 CDKN2A
5 response to inorganic substance GO:0010035 9.4 PTEN BAP1
6 positive regulation of apoptotic process GO:0043065 9.35 PTEN LATS2 LATS1 HMGB1 CDKN2A
7 regulation of organ growth GO:0046620 9.32 LATS2 LATS1
8 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.92 PTEN LATS2 LATS1 CDKN2A

Molecular functions related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 PTEN LATS1 ESR1 EGFR CDKN2A
2 identical protein binding GO:0042802 9.17 PTEN PGR MET ESR1 EGFR CLDN15
3 nitric-oxide synthase regulator activity GO:0030235 8.96 ESR1 EGFR

Sources for Peritoneal Mesothelioma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....